Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1885 results
January 2017
-
Press release
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet… -
Story From Our Labs
Countering the genome reprogramming of cancer cells
Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model
-
Press release
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in… -
Press release
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers… -
Press release
Novartis erzielt 2016 solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust der Exklusivrechte für Gleevec in den USA wettmachen; Innovationsdynamik hält an; Aktienrückkauf angekündigt
Der Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170… -
Press release
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow… -
Press release
Novartis: solide performance en 2016, les produits de croissance[1] absorbant la perte d'exclusivité de Gleevec aux USA; dynamique continue d'innovation; rachat d'actions annoncé
Chiffre d'affaires net de l'exercice 2016 (0% tcc[2]) comparable à celui de l'exercice précédent, grâce à l'excellente performance des produits de croissance Cosentyx (USD 1,1 milliard) a… -
Featured News
Improving diabetes awareness and treatment adherence in India
Through a successful patient support program, Novartis is taking diabetes care beyond the pill in India.
-
Story Discovery
Women in Science: Virginia Lazala
Lazala has been recognized by Hispanic Executive magazine for her commitment to mentoring students and colleagues.
-
Press release
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with… -
Story Patient Perspectives
A New Year’s resolution for COPD
Discover how COPD assessment and treatment are changing.